<DOC>
	<DOCNO>NCT01018563</DOCNO>
	<brief_summary>An open label extension MORAb-003-002 study order continue active patient MORAb-003-002 study maintenance MORAb-003 infusion main study close .</brief_summary>
	<brief_title>An Open Label Extension Study Efficacy MORAb-003</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<criteria>Provision Informed consent Subjects must enrol met inclusion/exclusion criterion MORAb003002 study . Subjects must achieve normalization CA 125 level and/or CR PR ( stable disease investigator 's assessment clinical benefit ) MORAb003 combination standard chemotherapy yet meet criterion disease progression participation MORAb003002 study . Subjects must currently receive singleagent MORAb003 maintenance therapy . Subjects discontinue MORAb003002 study reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Extension study</keyword>
	<keyword>Epithelial ovarian cancer</keyword>
</DOC>